{"id":"pneumococcal-vaccine","safety":{"commonSideEffects":[{"rate":"20–50","effect":"Injection site pain, erythema, or swelling"},{"rate":"10–20","effect":"Fever"},{"rate":"10–20","effect":"Myalgia or fatigue"},{"rate":"5–15","effect":"Headache"}]},"_chembl":null,"_dailymed":{"setId":"1158fa93-ef41-4a29-8252-9251f94c53c8","title":"VAXNEUVANCE (PNEUMOCOCCAL 15-VALENT CONJUGATE VACCINE CRM197 PROTEIN ADSORBED) INJECTION, SUSPENSION [MERCK SHARP & DOHME LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains pneumococcal polysaccharide antigens (or conjugated polysaccharide-protein complexes in newer formulations) that trigger both humoral and cell-mediated immune responses. This priming enables the immune system to rapidly recognize and eliminate pneumococcal pathogens upon natural exposure, preventing invasive pneumococcal disease including pneumonia, bacteremia, and meningitis.","oneSentence":"A pneumococcal vaccine stimulates the immune system to produce antibodies and cellular immunity against Streptococcus pneumoniae bacteria.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:44.807Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive pneumococcal disease (pneumonia, bacteremia, meningitis)"},{"name":"Prevention of pneumococcal otitis media and sinusitis"}]},"trialDetails":[{"nctId":"NCT07251465","phase":"","title":"A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2026-01-21","conditions":"Pneumonia","enrollment":846279},{"nctId":"NCT07242092","phase":"PHASE4","title":"Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-03-25","conditions":"Autoimmune Rheumatic Diseases","enrollment":192},{"nctId":"NCT07300267","phase":"PHASE1","title":"A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-13","conditions":"Pneumococcal Infection","enrollment":210},{"nctId":"NCT04460313","phase":"NA","title":"Nasopharyngeal Carriage of S. Pneumoniae","status":"RECRUITING","sponsor":"Association Clinique Thérapeutique Infantile du val de Marne","startDate":"2001-09-11","conditions":"Nasopharyngeal Carriage, Children, Only, Antibiotic Resistant Strain","enrollment":25760},{"nctId":"NCT07425392","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination","status":"RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2026-02-09","conditions":"Pneumococcal Vaccines","enrollment":720},{"nctId":"NCT06077656","phase":"PHASE2","title":"Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"Inventprise Inc.","startDate":"2023-10-25","conditions":"Pneumococcal Vaccines","enrollment":220},{"nctId":"NCT07284654","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49","status":"RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2025-12-01","conditions":"Pneumococcal Vaccines","enrollment":4000},{"nctId":"NCT07216430","phase":"PHASE2","title":"Safety and Efficacy of wSp Vaccine in Young Children","status":"RECRUITING","sponsor":"Serum Life Science Europe GmbH","startDate":"2025-09-29","conditions":"Acute Otitis Media (AOM)","enrollment":320},{"nctId":"NCT07135453","phase":"PHASE4","title":"Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-03","conditions":"Vaccine, Pneumococcal Disease","enrollment":70},{"nctId":"NCT07023081","phase":"PHASE1","title":"A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2025-06-15","conditions":"Pneumococcal Disease","enrollment":200},{"nctId":"NCT06622109","phase":"","title":"A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-11-25","conditions":"Pneumococcal Disease","enrollment":1100},{"nctId":"NCT06760208","phase":"","title":"A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-11-13","conditions":"Pneumococcal Immunization, Safety","enrollment":660},{"nctId":"NCT06177912","phase":"PHASE3","title":"A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-01-18","conditions":"Pneumococcal Infection","enrollment":882},{"nctId":"NCT06782282","phase":"","title":"A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2025-01-20","conditions":"Community-Acquired Pneumonia (CAP)","enrollment":22234435},{"nctId":"NCT06531538","phase":"PHASE2","title":"A Study to Learn About How a New Pneumococcal Vaccine Works in Children","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-07-30","conditions":"Pneumococcal Disease","enrollment":225},{"nctId":"NCT07460154","phase":"NA","title":"Structured Review: To Optimise Management and Prevent Harm in COPD","status":"NOT_YET_RECRUITING","sponsor":"Northumbria Healthcare NHS Foundation Trust","startDate":"2026-03-01","conditions":"COPD","enrollment":96},{"nctId":"NCT03650114","phase":"PHASE3","title":"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-28","conditions":"Relapsing Multiple Sclerosis","enrollment":1882},{"nctId":"NCT07365826","phase":"PHASE3","title":"A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age","status":"RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2026-01-12","conditions":"Pneumococcal Vaccines","enrollment":1300},{"nctId":"NCT06049134","phase":"PHASE4","title":"Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-10-06","conditions":"Lymphoma","enrollment":30},{"nctId":"NCT07252791","phase":"PHASE4","title":"Safety and Immunogenicity of PCV20 in Pediatric Patients With Autoimmune Rheumatic Diseases","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-01-16","conditions":"Autoimmune Rheumatologic Disease","enrollment":114},{"nctId":"NCT06128915","phase":"PHASE4","title":"The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses","status":"RECRUITING","sponsor":"State University of New York at Buffalo","startDate":"2024-01-08","conditions":"Aging","enrollment":60},{"nctId":"NCT05696080","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-02-13","conditions":"Pneumococcal Infection","enrollment":518},{"nctId":"NCT06824194","phase":"PHASE3","title":"Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-02-18","conditions":"Pneumococcal Immunization","enrollment":2320},{"nctId":"NCT06975878","phase":"PHASE3","title":"Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-05-22","conditions":"Pneumococcal Immunization, Healthy Volunteers","enrollment":1092},{"nctId":"NCT05569954","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-11-07","conditions":"Pneumococcal Disease","enrollment":1484},{"nctId":"NCT07017777","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)","status":"RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2025-11-14","conditions":"Pneumococcal Infections, Streptococcal Infections, Bacterial Infections","enrollment":600},{"nctId":"NCT07019909","phase":"PHASE1","title":"A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-07-06","conditions":"Pneumococcal Disease","enrollment":400},{"nctId":"NCT07348692","phase":"PHASE3","title":"Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-01-20","conditions":"Pneumococcal Immunization, Healthy Volunteers","enrollment":896},{"nctId":"NCT03942328","phase":"PHASE1, PHASE2","title":"Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2019-09-19","conditions":"Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8","enrollment":85},{"nctId":"NCT07428759","phase":"PHASE1","title":"Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-03-10","conditions":"Pneumonia, Bacterial","enrollment":120},{"nctId":"NCT00339157","phase":"PHASE2, PHASE3","title":"Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2006-05-11","conditions":"Systemic-Onset Juvenile Idiopathic Arthritis","enrollment":24},{"nctId":"NCT06181656","phase":"","title":"Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-02-05","conditions":"Pneumococcal Vaccine, Esophageal Cancer, Lymphopenia","enrollment":80},{"nctId":"NCT06736041","phase":"PHASE3","title":"Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-12-18","conditions":"Pneumococcal Immunization","enrollment":1714},{"nctId":"NCT07418372","phase":"PHASE1, PHASE2","title":"Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2026-03-12","conditions":"Tetanus, Diphtheria and Acellular Pertussis Vaccination, Tetanus, Diphtheria","enrollment":660},{"nctId":"NCT05183854","phase":"PHASE2","title":"Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial","status":"RECRUITING","sponsor":"University of Utah","startDate":"2022-01-31","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":60},{"nctId":"NCT06824181","phase":"PHASE3","title":"Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-02-27","conditions":"Pneumococcal Immunization","enrollment":580},{"nctId":"NCT07406334","phase":"PHASE1","title":"A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months of Age Receiving a Single Booster Dose","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-05-15","conditions":"Pneumonia, Bacterial","enrollment":45},{"nctId":"NCT07406347","phase":"PHASE1","title":"A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-07-10","conditions":"Pneumonia, Bacterial","enrollment":60},{"nctId":"NCT03621670","phase":"PHASE3","title":"Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-07-27","conditions":"Infections, Meningococcal","enrollment":1196},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT05393037","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-13","conditions":"Pneumococcal Disease","enrollment":313},{"nctId":"NCT07160244","phase":"PHASE3","title":"BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-08-25","conditions":"Healthy","enrollment":6000},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT04745559","phase":"PHASE2","title":"Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-02-18","conditions":"Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (TFL)","enrollment":26},{"nctId":"NCT06183216","phase":"PHASE1","title":"A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2024-01-04","conditions":"Pneumococcal Infectious Disease","enrollment":140},{"nctId":"NCT07247188","phase":"PHASE3","title":"Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-01-20","conditions":"Sickle Cell Disease","enrollment":100},{"nctId":"NCT06550830","phase":"PHASE1","title":"Clinical Trial of PCV24 in Children Aged 2-17 Years","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2024-09-07","conditions":"Pneumococcal Infectious Disease","enrollment":119},{"nctId":"NCT06800261","phase":"PHASE1","title":"Clinical Trial of PCV24 in Infants Aged 2-23 Months","status":"RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2025-05-08","conditions":"Pneumococcal Infectious Disease","enrollment":180},{"nctId":"NCT06617715","phase":"PHASE3","title":"Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine","status":"RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2024-10-23","conditions":"Pneumococcal Infectious Disease","enrollment":3080},{"nctId":"NCT05092386","phase":"PHASE1","title":"Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2023-01-03","conditions":"Pneumococcal Infections","enrollment":310},{"nctId":"NCT05452941","phase":"","title":"A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-10-27","conditions":"Pneumonia","enrollment":12500},{"nctId":"NCT05622682","phase":"","title":"Vaccine Immune Recovery After Leukemia","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2022-09-28","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":89},{"nctId":"NCT06720038","phase":"PHASE2","title":"A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2024-11-25","conditions":"Pneumococcal Vaccines","enrollment":905},{"nctId":"NCT04193215","phase":"PHASE3","title":"V114 and Acute Otitis Media (V114-032/PNEU-ERA)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-09-12","conditions":"Acute Otitis Media (AOM)","enrollment":7119},{"nctId":"NCT07286370","phase":"PHASE2","title":"A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-02-16","conditions":"Salmonella Infections","enrollment":537},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT06647407","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-05","conditions":"Meningococcal Immunization, Healthy Volunteers","enrollment":750},{"nctId":"NCT07333352","phase":"PHASE2","title":"PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months","status":"RECRUITING","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2025-09-11","conditions":"Pneumococcal Infectious Disease","enrollment":480},{"nctId":"NCT02518555","phase":"PHASE2","title":"Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jennifer Woyach","startDate":"2016-01-12","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":42},{"nctId":"NCT05417165","phase":"PHASE2","title":"Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"Seema Bhat","startDate":"2023-09-29","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":80},{"nctId":"NCT07071909","phase":"PHASE1, PHASE2","title":"Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells","status":"WITHDRAWN","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2025-01-20","conditions":"Malignancy, Cancer, Hematological Malignancies","enrollment":""},{"nctId":"NCT05815264","phase":"PHASE1","title":"Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above","status":"COMPLETED","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2020-09-07","conditions":"Pneumonia","enrollment":144},{"nctId":"NCT06675032","phase":"PHASE1","title":"Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2024-04-27","conditions":"Pneumococcal Infectious Disease","enrollment":230},{"nctId":"NCT07105722","phase":"PHASE1","title":"A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-08-12","conditions":"Pneumonia, Bacterial","enrollment":127},{"nctId":"NCT07300644","phase":"PHASE2","title":"Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years","status":"RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2025-11-25","conditions":"Pneumococcal Infectious Disease","enrollment":420},{"nctId":"NCT06822907","phase":"PHASE4","title":"Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2026-01","conditions":"Acute Febrile Illness, Pneumococcal Infections","enrollment":1052},{"nctId":"NCT06817421","phase":"PHASE4","title":"Opportunistic Pneumococcal Immunisation Trial in MALnutrition","status":"NOT_YET_RECRUITING","sponsor":"Nick Fancourt","startDate":"2026-01","conditions":"Severe Acute Malnutrition in Childhood, Pneumococcal Disease, Pneumococcal Vaccines","enrollment":214},{"nctId":"NCT06678620","phase":"PHASE2","title":"Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2024-04-20","conditions":"Pneumococcal Infectious Disease","enrollment":992},{"nctId":"NCT05512819","phase":"PHASE3","title":"A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-09-16","conditions":"Pneumococcal Disease","enrollment":541},{"nctId":"NCT07243236","phase":"","title":"Impact of Vaccine Funding by the National Health Insurance on Vaccination Coverage Among Patients Targeted by Current Vaccination Recommendations and Followed in Outpatient Consultations","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-11-19","conditions":"Healthcare Providers, Postpartum","enrollment":2920},{"nctId":"NCT02232191","phase":"PHASE2","title":"Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2014-12","conditions":"Asplenia","enrollment":75},{"nctId":"NCT06806137","phase":"PHASE3","title":"A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-05-15","conditions":"Chickenpox","enrollment":600},{"nctId":"NCT05060146","phase":"NA","title":"Prevention of Pneumococcal Infections: Impact Collaborative Medico-pharmaceutical Care Structured to Improve Vaccination Coverage of Patients at Risk.","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2022-09-19","conditions":"Streptococcus Pneumoniae Infection","enrollment":646},{"nctId":"NCT06855160","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-04-17","conditions":"Chickenpox","enrollment":900},{"nctId":"NCT01351896","phase":"PHASE2","title":"Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-11-02","conditions":"Ann Arbor Stage I Small Lymphocytic Lymphoma, Ann Arbor Stage II Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia","enrollment":49},{"nctId":"NCT03069703","phase":"PHASE2","title":"Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-02-05","conditions":"Invasive Pneumococcal Infection","enrollment":96},{"nctId":"NCT02052154","phase":"PHASE2","title":"Multicenter Pilot Study Evaluating the Immunogenicity of an Innovative Pneumococcal Vaccination Strategy in Splenectomized Adults","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2014-03-10","conditions":"Splenectomized Patients","enrollment":70},{"nctId":"NCT07135427","phase":"PHASE4","title":"Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-09-03","conditions":"Alpha 1-Antitrypsin, COPD, Antibody Deficiency","enrollment":30},{"nctId":"NCT05526716","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-09-23","conditions":"Pneumonia, Pneumococcal","enrollment":1080},{"nctId":"NCT07059182","phase":"PHASE1","title":"Safety Study of a Single Dose of Pneumococcal Whole-Cell Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Serum Life Science Europe GmbH","startDate":"2025-06-11","conditions":"PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE, Prevention of Pneumococcal-induced Acute Otitis Media","enrollment":30},{"nctId":"NCT05412030","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-06-16","conditions":"Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal","enrollment":388},{"nctId":"NCT05794191","phase":"","title":"A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-03-22","conditions":"HIV, Pneumonia, Infections, Pneumococcal","enrollment":350399},{"nctId":"NCT06182124","phase":"PHASE1, PHASE2","title":"A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-12-20","conditions":"Pneumococcal Disease","enrollment":558},{"nctId":"NCT06838000","phase":"PHASE3","title":"Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2025-02-28","conditions":"Pneumococcal Infections","enrollment":1268},{"nctId":"NCT07205289","phase":"PHASE1","title":"Serum Collection Study for Assay Development","status":"RECRUITING","sponsor":"GPN Vaccines","startDate":"2025-10","conditions":"Pneumococcal Disease, Invasive, Pneumococcal Disease","enrollment":12},{"nctId":"NCT04429295","phase":"PHASE3","title":"Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-06-28","conditions":"Pertussis Immunisation, Diphtheria Immunisation, Polio Immunisation","enrollment":460},{"nctId":"NCT05155579","phase":"PHASE1","title":"Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2022-05-14","conditions":"Malaria","enrollment":593},{"nctId":"NCT06784167","phase":"","title":"Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-03-10","conditions":"Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":45},{"nctId":"NCT05844423","phase":"PHASE2","title":"Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants","status":"COMPLETED","sponsor":"Vaxcyte, Inc.","startDate":"2023-03-29","conditions":"Pneumococcal Vaccines","enrollment":802},{"nctId":"NCT06038617","phase":"PHASE4","title":"Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2023-10-30","conditions":"Fever After Vaccination, Fever, Seizures Fever","enrollment":344},{"nctId":"NCT00611663","phase":"PHASE2, PHASE3","title":"Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-05","conditions":"Lupus Erythematosus, Systemic","enrollment":47},{"nctId":"NCT04583618","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-10-08","conditions":"Pneumococcal Immunization","enrollment":750},{"nctId":"NCT04398706","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-05-22","conditions":"Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":852},{"nctId":"NCT06524414","phase":"PHASE2","title":"A Study to Learn About How a New Pneumococcal Vaccine Works in Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-07-25","conditions":"Pneumococcal Disease","enrollment":605},{"nctId":"NCT03859687","phase":"PHASE1","title":"Trial of Antibody Responses by Vitamin Supplementation","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-08-19","conditions":"Healthy Participants","enrollment":22},{"nctId":"NCT04078997","phase":"","title":"An Evaluation of PCV13 Vaccine Schedules, Comparing Impact of 2+1 vs 3+0 on Pneumococcal Carriage in Blantyre, Malawi","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2019-07-21","conditions":"13-valent Pneumococcal Vaccine, Streptococcus Pneumoniae","enrollment":3507},{"nctId":"NCT07154537","phase":"PHASE4","title":"Pneumococcal Conjugated Vaccine 13 (PCV13) for Patients With Multiple Myeloma (MM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2016-03-23","conditions":"Multiple Myeloma","enrollment":101},{"nctId":"NCT06790290","phase":"PHASE2","title":"Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Inventprise Inc.","startDate":"2025-01-27","conditions":"Pneumococcal Disease, Invasive","enrollment":421},{"nctId":"NCT02126384","phase":"NA","title":"Identifocation the B Cell Subsets Responsible for Anti-pneumococcal Response","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2014-11-18","conditions":"Pneumococcal Diseases","enrollment":9},{"nctId":"NCT03376477","phase":"PHASE2","title":"Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-09-23","conditions":"Multiple Myeloma","enrollment":24}],"_emaApprovals":[],"_faersSignals":[{"count":386,"reaction":"DYSPNOEA"},{"count":284,"reaction":"FATIGUE"},{"count":261,"reaction":"COUGH"},{"count":255,"reaction":"PAIN"},{"count":250,"reaction":"ASTHMA"},{"count":226,"reaction":"HEADACHE"},{"count":215,"reaction":"WHEEZING"},{"count":209,"reaction":"DRUG INEFFECTIVE"},{"count":201,"reaction":"GASTROOESOPHAGEAL REFLUX DISEASE"},{"count":194,"reaction":"PYREXIA"}],"_approvalHistory":[],"publicationCount":3668,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Prevnar","Prevenar","Pneumovax","vaccine with pneumococcal polysaccharides of 13 different serotypes conjugated to a protein (Prevnar13)","20-valent pneumococcal conjugate vaccine"],"phase":"marketed","status":"active","brandName":"Pneumococcal (vaccine)","genericName":"Pneumococcal (vaccine)","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Biologic","firstApprovalDate":"","aiSummary":"A pneumococcal vaccine stimulates the immune system to produce antibodies and cellular immunity against Streptococcus pneumoniae bacteria. Used for Prevention of invasive pneumococcal disease (pneumonia, bacteremia, meningitis), Prevention of pneumococcal otitis media and sinusitis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}